Post
of 161,624
when maraviroc was approved in 2007 it was needed. it was better than the terrible options that were SOC at the time. now its a salvage therapy used only when they have run out of ideas. its junk.
other drugs approved since than have raised the bar considerably. leronlimab is as good as SOC, but without a long acting option, its not an attractive option. long acting drugs are where its at in hiv. plus the indication in hiv that is relevant is very small. mdr-hiv R5-tropic is a very small fraction of all hiv patients, and they would be head to head with gilead's drug which is very similar in effectiveness as well as safety. and Lenacapavir is even available in pill form.
a small biotech with very limited resources needs to choose its indications carefully. compare the above to mss-crc. in mss-crc heavily treated patients, the SOC is horrendous, very low bar. and the size of the indication is very very big. hence here we are, perhaps on the verge of that one big break.
other drugs approved since than have raised the bar considerably. leronlimab is as good as SOC, but without a long acting option, its not an attractive option. long acting drugs are where its at in hiv. plus the indication in hiv that is relevant is very small. mdr-hiv R5-tropic is a very small fraction of all hiv patients, and they would be head to head with gilead's drug which is very similar in effectiveness as well as safety. and Lenacapavir is even available in pill form.
a small biotech with very limited resources needs to choose its indications carefully. compare the above to mss-crc. in mss-crc heavily treated patients, the SOC is horrendous, very low bar. and the size of the indication is very very big. hence here we are, perhaps on the verge of that one big break.
8
1